Literature DB >> 15154004

Expression of cell cycle inhibitor p27Kip1 and its inactivator Jab1 in melanocytic lesions.

Doina Ivan1, A Hafeez Diwan, Francisco J Esteva, Victor G Prieto.   

Abstract

Decreased expression of p27 (a cyclin-dependent kinase inhibitor) is an adverse prognostic marker in a diverse array of human cancers. The purpose of this study was to investigate the expression of p27 and Jab1 (a protein involved in p27 degradation) in melanocytic lesions, and to identify their possible participation in melanoma progression. A tissue microarray was constructed using formalin-fixed, paraffin-embedded archival tissue blocks of 94 melanocytic lesions including 19 benign nevi, 21 dysplastic nevi, 23 melanomas, and 31 metastatic melanomas. The expression of p27 and Jab1 was evaluated by immunohistochemistry. The association between p27, Jab1, and clinicopathological parameters was analyzed using chi2 and Fisher's exact tests. Nonparametric Pearson's rank correlation was applied to evaluate the relationship between p27 and Jab1 expression. p27 was expressed in 15 (88%) nevi, 18 (95%) dysplastic nevi, 11 (50%) melanomas, and only in four (13%) of the metastatic melanomas (P<0.001). Jab1 was expressed in 14 (82%) standard nevi, 18 (95%) dysplastic nevi, 17 (77%) melanomas, and 16 (53%) of the metastatic melanomas (P<0.01). In metastatic melanomas, there was a negative correlation between p27 and Jab1 expression (r=-0.166). The low levels of p27 in primary and metastatic melanoma cases may explain the high proliferation rate of such lesions. Also, the relative high expression of Jab1 in metastatic melanoma, associated with low levels of p27, suggests that Jab1 may be involved in survival and proliferation of metastatic melanoma cells. Copyright 2004 USCAP, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15154004     DOI: 10.1038/modpathol.3800123

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  15 in total

1.  Immunohistochemical expression of p16, p21, p27 and cyclin D1 in oral nevi and melanoma.

Authors:  Bruno Augusto Benevenuto de Andrade; Jorge Esquiche León; Román Carlos; Wilson Delgado-Azañero; Adalberto Mosqueda-Taylor; Oslei Paes de Almeida
Journal:  Head Neck Pathol       Date:  2012-02-05

2.  Advances in cancer tissue microarray technology: Towards improved understanding and diagnostics.

Authors:  Wenjin Chen; David J Foran
Journal:  Anal Chim Acta       Date:  2006-01-23       Impact factor: 6.558

3.  Adhesion to fibronectin induces p27(Kip1) nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-mediated drug resistance (CAM-DR) in RPMI 8,226 cells.

Authors:  Min Fei; Qinglei Hang; Sicong Hou; Songbin He; Changgeng Ruan
Journal:  Mol Cell Biochem       Date:  2013-10-30       Impact factor: 3.396

4.  Jab1 promotes glioma cell proliferation by regulating Siah1/β-catenin pathway.

Authors:  Yufu Zhu; Zhichao Qiu; Xiang Zhang; Fengyuan Qian; Bin Wang; Lei Wang; Hengliang Shi; Rutong Yu
Journal:  J Neurooncol       Date:  2016-09-17       Impact factor: 4.130

5.  Potential role of Jun activation domain-binding protein 1 as a negative regulator of p27kip1 in pancreatic adenocarcinoma.

Authors:  Maria A Kouvaraki; Anita L Korapati; George Z Rassidakis; Ling Tian; Qingxiu Zhang; Paul Chiao; Linus Ho; Douglas B Evans; François X Claret
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

Review 6.  The emerging role of the COP9 signalosome in cancer.

Authors:  Katharine S Richardson; Wayne Zundel
Journal:  Mol Cancer Res       Date:  2005-12       Impact factor: 5.852

7.  Stable form of JAB1 enhances proliferation and maintenance of hematopoietic progenitors.

Authors:  Masaaki Mori; Noriko Yoneda-Kato; Akihiro Yoshida; Jun-ya Kato
Journal:  J Biol Chem       Date:  2008-07-30       Impact factor: 5.157

8.  JAB1/CSN5: a new player in cell cycle control and cancer.

Authors:  Terry J Shackleford; Francois X Claret
Journal:  Cell Div       Date:  2010-10-18       Impact factor: 5.130

Review 9.  Delivery strategies and potential targets for siRNA in major cancer types.

Authors:  So Jin Lee; Min Ju Kim; Ick Chan Kwon; Thomas M Roberts
Journal:  Adv Drug Deliv Rev       Date:  2016-05-31       Impact factor: 15.470

10.  Molecular markers of tumor progression in melanoma.

Authors:  Joshua Rother; Dan Jones
Journal:  Curr Genomics       Date:  2009-06       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.